Charles Schwab’s Trillium Therapeutics Inc. TRIL Stock Holding History

Charles Schwab’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-213,112	Closed	-$3.74M	–	3625
2021 Q3	$3.74M	Buy	213,112 +5,759	+3%	+$67.3K	﹤0.01%	2505
2021 Q2	$2.01M	Buy	+207,353	New	+$1.95M	﹤0.01%	2711

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Charles Schwab's TRIL Position: Q4 2021 in Review

Charles Schwab sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 213,112 shares — an estimated $3.74M sold.

Charles Schwab first reported a position in TRIL in Q2 2021 and held it in 2 quarters. The position peaked at $3.74M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Charles Schwab reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Charles Schwab sold 213,112 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $3.74M.
Charles Schwab first reported a position in Trillium Therapeutics Inc. in Q2 2021 and held it in 2 quarters.
Charles Schwab's Trillium Therapeutics Inc. position peaked at $3.74M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Charles Schwab's 13F filing for Q4 2021, filed 11 Feb 2022.